The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected… The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected…

MLB Sees Dramatic Drop In PED Suspensions

2025/12/03 21:41

Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions.

getty

Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing.

If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16.

The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances.

Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D.

For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,300.

Of those tests, two resulted in adverse findings that led to suspensions. In all cases, players are retested if there are adverse findings. Should the findings remain and fall under the substances that result in suspension, a player can appeal the suspension. Therefore, when a suspension is announced, it is a considerable period of time after the player tests positive for PEDs.

For 2025, there were two players suspended for violating the drug program:

On May 18th, José Alvarado received an 80-game suspension without pay after testing positive for exogenous Testosterone. On May 31st, Jurickson Profar received an 80-game suspension without pay after testing positive for Chorionic Gonadotrophin (hCG). In both cases, the suspensions were for performance-enhancing substances.

Therapeutic Use Exemptions For Otherwise Banned Substances

The league and MLBPA have allowed a system in which players, through a doctor’s care, and apply for what is called a Therapeutic Use Exemption, or TUEs. The TUEs is granted after comprehensive medical documentation to prove the medical need for the medication and demonstrate that the treatment only returns the athlete to a normal level of health, rather than providing an unfair advantage. In the vast majority of the TUEs granted each year, the exemption is made for Attention Deficit Hyperactivity Disorder (ADHD) medications. These medications are often amphetamine derivatives, and given that amphetamines are banned in MLB, the player would need an exemption to use such meds to address ADHD.

In years past, the number of ADHD TUEs has reached over 100, which raised the question as to whether there was a fundamental loophole in the drug testing program.

But over the years, these numbers have declined dramatically. For 2025, there was a total of 57 TUEs granted, with 54 for ADHD, along with one each granted for hypertension, sleep disorder, and hormone function. In all cases, the players granted TUEs are not released in the annual report. The drug testing program does not allow for therapeutic use exemptions for human growth hormone.

The 57 total therapeutic use exemptions in 2025 is a -37% drop from the 91 granted in 2020, and shows the drop over just the past six years. While there will likely never be a day when there are no suspensions and no therapeutic use exemptions, for now, at least within the drug program, Major League Baseball is about as free from PEDs as it may ever be.

The table below shows the number of PED suspensions, the total number of therapeutic use exemptions, and the number of those that are ADHD related from 2020 to 2025.

Graphical representation of MLB drug suspension, TUEs, and those that are for ADHD

Maury Brown

Source: https://www.forbes.com/sites/maurybrown/2025/12/03/mlb-sees-dramatic-drop-in-ped-suspensions/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

The post Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 20:26 While meme tokens like Pepe Coin and established networks such as Tron attract headlines, many investors are now searching for projects that combine innovation, revenue-sharing and real-world utility. BlockchainFX ($BFX), currently in presale at $0.024 ahead of an expected $0.05 launch, is quickly becoming one of the best cryptos to buy today. With $7m already secured and a unique model spanning multiple asset classes, it is positioning itself as a decentralised super app and a contender to surpass older altcoins. Early Presale Pricing Creates A Rare Entry Point BlockchainFX’s presale pricing structure has been designed to reward early participants. At $0.024, buyers secure a lower entry price than later rounds, locking in a cost basis more than 50% below the projected $0.05 launch price. As sales continue to climb beyond $7m, each new stage automatically increases the token price. This built-in mechanism creates a clear advantage for early investors and explains why the project is increasingly cited in “best presales to buy now” discussions across the crypto space. High-Yield Staking Model Shares Platform Revenue Beyond its presale appeal, BlockchainFX is creating a high-yield staking model that gives holders a direct share of platform revenue. Every time a trade occurs on its platform, 70% of trading fees flow back into the $BFX ecosystem: 50% of collected fees are automatically distributed to stakers in both BFX and USDT. 20% is allocated to daily buybacks of $BFX, adding demand and price support. Half of the bought-back tokens are permanently burned, steadily reducing supply. Rewards are based on the size of each member’s BFX holdings and capped at $25,000 USDT per day to ensure sustainability. This structure transforms token ownership from a speculative bet into an income-generating position, a rare feature among today’s altcoins. A Multi-Asset Platform…
Share
BitcoinEthereumNews2025/09/18 03:35
Here’s How Consumers May Benefit From Lower Interest Rates

Here’s How Consumers May Benefit From Lower Interest Rates

The post Here’s How Consumers May Benefit From Lower Interest Rates appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday opted to ease interest rates for the first time in months, leading the way for potentially lower mortgage rates, bond yields and a likely boost to cryptocurrency over the coming weeks. Average long-term mortgage rates dropped to their lowest levels in months ahead of the central bank’s policy shift. Copyright{2018} The Associated Press. All rights reserved. Key Facts The central bank’s policymaking panel voted this week to lower interest rates, which have sat between 4.25% and 4.5% since December, to a new range of 4% and 4.25%. How Will Lower Interest Rates Impact Mortgage Rates? Mortgage rates tend to fall before and during a period of interest rate cuts: The average 30-year fixed-rate mortgage dropped to 6.35% from 6.5% last week, the lowest level since October 2024, mortgage buyer Freddie Mac reported. Borrowing costs on 15-year fixed-rate mortgages also dropped to 5.5% from 5.6% as they neared the year-ago rate of 5.27%. When the Federal Reserve lowered the funds rate to between 0% and 0.25% during the pandemic, 30-year mortgage rates hit record lows between 2.7% and 3% by the end of 2020, according to data published by Freddie Mac. Consumers who refinanced their mortgages in 2020 saved about $5.3 billion annually as rates dropped, according to the Consumer Financial Protection Bureau. Similarly, mortgage rates spiked around 7% as interest rates were hiked in 2022 and 2023, though mortgage rates appeared to react within weeks of the Fed opting to cut or raise rates. How Do Treasury Bonds Respond To Lower Interest Rates? Long-term Treasury yields are more directly influenced by interest rates, as lower rates tend to result in lower yields. When the Fed pushed rates to near zero during the pandemic, 10-year Treasury yields fell to an all-time low of 0.5%. As…
Share
BitcoinEthereumNews2025/09/18 05:59